SYSA1901 (pertuzumab biosimilar) / CSPC Pharma - LARVOL DELTA

MARKETING AUTHORISATION APPLICATION FOR PERTUZUMAB INJECTION ACCEPTED BY THE NMPA (HKEXnews) - "The Product has been applied for as a Class 3.3 therapeutic biological product. It is indicated for the treatment of HER2-positive breast cancer. The Product is a recombinant humanised anti-HER2 monoclonal antibody injection administered once every three weeks....This application is primarily supported by a Phase III equivalence clinical trial enrolling patients with early-stage or locally advanced HER2-positive breast cancer."

China filing • HER2 Positive Breast Cancer